| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Nifuratel targets multiple pathogens including bacteria, fungi, and protozoa. As a nitrofuran derivative, its mechanism involves the generation of reactive intermediates that damage microbial DNA and proteins. The compound inhibits bacterial and fungal growth through disruption of cellular processes. It has broad-spectrum antimicrobial activity. The compound also shows anticancer and anti-inflammatory activities.
|
|---|---|
| ln Vitro |
In vitro, Nifuratel shows potent antimicrobial activity with an IC₅₀/MIC of 0.125-1 μg/mL against A. vaginae. It has good inhibitory effects on Candida and Trichomonas. It inhibits SARS-CoV-2-induced cytotoxicity in Caco-2 and VERO-6 cells. The compound significantly inhibits the growth and proliferation of human gastric cancer cells. Detailed in vitro data are available in the microbiological and pharmacological literature.
|
| ln Vivo |
In vivo, Nifuratel is an orally active antibiotic used for the treatment of vulvo-vaginal infections. It has been used clinically for the treatment of vaginal infections including trichomoniasis and candidiasis. The compound's efficacy and safety have been evaluated in clinical studies. Detailed in vivo data are available in clinical pharmacology literature.
|
| Enzyme Assay |
In vitro antimicrobial susceptibility testing for Nifuratel typically uses broth microdilution or agar dilution methods according to CLSI guidelines. The compound is dissolved in DMSO or appropriate solvent and serially diluted in growth medium. Bacterial or fungal cultures are inoculated at standard densities and incubated at 37°C for 18-24 hours. Minimum inhibitory concentration (MIC) is determined as the lowest concentration inhibiting visible growth. For antiviral assays, cells are infected with SARS-CoV-2 and treated with compound; cytotoxicity is measured. Controls include vehicle and reference antibiotics.
|
| Cell Assay |
For cell-based assays, relevant cell lines (e.g., cancer cells, Caco-2, VERO-6) are cultured in DMEM or RPMI-1640 with 10% FBS. Cells are seeded in 96-well plates and treated with Nifuratel at various concentrations for 24-72 hours. Cell viability is assessed by MTT or CellTiter-Glo. Antiviral activity is assessed by measuring virus-induced cytopathic effect or viral load. Anti-inflammatory activity may be assessed by measuring cytokine production. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, Nifuratel is typically administered orally to patients. For vaginal infections, it may be administered locally. Dosing regimens are established based on clinical use. For animal studies, rodents are dosed orally or via other routes. Efficacy is assessed by microbial load reduction or symptom improvement. Pharmacokinetic parameters are determined from plasma samples. All procedures follow institutional guidelines.
|
| ADME/Pharmacokinetics |
Nifuratel (MW 285.28, C₁₀H₁₁N₃O₅S) is an orally active antibiotic. It is a nitrofuran derivative. The compound is absorbed orally and distributed to tissues. It is metabolized and excreted. Detailed pharmacokinetic parameters are available from pharmacological literature. The compound is available as a pharmaceutical product in some countries.
|
| Toxicity/Toxicokinetics |
Nifuratel has been used clinically and has an established safety profile. It is generally well-tolerated at therapeutic doses. Side effects are typically mild. The compound is contraindicated in patients with nitrofuran hypersensitivity. Standard precautions for antibiotic use apply. The compound is available as a drug in some countries.
|
| Additional Infomation |
Nifuratel belongs to the furan class of compounds and is a C-nitro compound. It is used topically as an antiprotozoal and antifungal agent, and can also be taken orally.
Nifuratel is a broad-spectrum antibiotic used for the treatment of vulvo-vaginal infections, including trichomoniasis and candidiasis. It has antibacterial, antifungal, antiprotozoal, anticancer, and anti-inflammatory activities. The compound is available as a pharmaceutical product in some countries. It is also available from chemical suppliers for research purposes. Its mechanism involves nitrofuran-mediated antimicrobial activity. |
| Molecular Formula |
C10H11N3O5S
|
|---|---|
| Molecular Weight |
285.27
|
| Exact Mass |
285.041
|
| CAS # |
4936-47-4
|
| PubChem CID |
6433427
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
423.6±53.0 °C at 760 mmHg
|
| Melting Point |
176-178°C
|
| Flash Point |
210.0±30.9 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.666
|
| LogP |
0.27
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
386
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C([H])([H])[H])C([H])([H])C1([H])C([H])([H])N(C(=O)O1)/N=C(/[H])\C1=C([H])C([H])=C([N+](=O)[O-])O1
|
| InChi Key |
SRQKTCXJCCHINN-NYYWCZLTSA-N
|
| InChi Code |
InChI=1S/C10H11N3O5S/c1-19-6-8-5-12(10(14)18-8)11-4-7-2-3-9(17-7)13(15)16/h2-4,8H,5-6H2,1H3/b11-4+
|
| Chemical Name |
5-(methylsulfanylmethyl)-3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one
|
| Synonyms |
Magmilor; Macmiror; Nifuratel
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~175.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5055 mL | 17.5273 mL | 35.0545 mL | |
| 5 mM | 0.7011 mL | 3.5055 mL | 7.0109 mL | |
| 10 mM | 0.3505 mL | 1.7527 mL | 3.5055 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
